Vaccines and Infectious Diseases Analytics (VIDA)

Image sourced from TimesLIVE A lab study by Pfizer and BioNTech has shown that its COVID-19 vaccine has proven ‘less effective’ against the South African variant by producing “lower levels of neutralizing antibodies”. According to Bloomberg, the results are “part of tests of its vaccine against a lab-created virus that had all the mutations found in the South African variant, which is thought to spread faster than earlier versions”. “The mutant virus has become a stumbling block for vaccine campaigns, with South Africa halting the rollout of AstraZeneca Plc’s shot after a study showed it didn’t work as well in preventing mild illness involving the variant first identified there”. The AstraZeneca COVID-19 vaccine – of which South Africa has received one million doses – has proven ‘minimally...